Stock comparison
DexCom
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DXCM
DexCom
Market cap
$27.82B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DXCM | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 75B | IDXX |
| Benjamin Graham | 74B | 80A | IDXX |
| Philip Fisher | 75B | 75B | Tie |
| Peter Lynch | 61C | 71B | IDXX |
| Joel Greenblatt | 58C | 83C | IDXX |
| Charlie Munger | 66B | 87A | IDXX |
| Terry Smith | 66B | 84A | IDXX |
Side-by-side metrics
| Metric | DXCM | IDXX |
|---|---|---|
| Market cap | $27.82B | $44.12B |
| P/E (TTM) | 24.6x | 39.0x |
| EV/EBIT | 25.4x | 31.6x |
| ROIC (TTM) | 18.03% | 40.66% |
| Gross margin | 61.84% | 62.05% |
| Net margin | 19.31% | 24.63% |
| Revenue CAGR 5y | 17.47% | 7.56% |
| EPS CAGR 5y | 39.82% | 10.79% |
| Debt / Equity | 0.5x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DXCM leads on
- EPS CAGR 5y39.82%vs 10.79%+73%
- Revenue CAGR 5y17.47%vs 7.56%+57%
- P/E (TTM)24.6xvs 39.0x+37%
- Debt / Equity0.5xvs 0.7x+32%
IDXX leads on
- ROIC (TTM)40.66%vs 18.03%+56%
- Market cap$44.12Bvs $27.82B+37%
- Net margin24.63%vs 19.31%+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.